4.6 Article

The use of cyclosporine in dermatology: Part II

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2010.02.062

关键词

atopic dermatitis; calcineurin inhibitors; cyclosporine; diug interactions; pharmacokinetics; psoriasis

资金

  1. Elsevier
  2. 3M/Graceway Pharmaceuticals
  3. Genentech
  4. Astellas Pharmaceuticals
  5. Abbott
  6. Astellas
  7. Centocor
  8. Eli Lilly
  9. Novartis
  10. Novo Nordisk
  11. Pfizer
  12. Promius
  13. Syntrix
  14. Warner Chilcott

向作者/读者索取更多资源

Cyclosporine is highly effective in the treatment of a multitude of dermatoses. Concern over its side effect profile has limited its use in dermatology. Adverse effects are, for the most part, dose dependent and related to duration of therapy. Using the recommended monitoring protocols results in a significant decrease in the incidence of cyclosporine-related toxicities. This article provides a comprehensive review of the pharmacokinetics of cyclosporine, potential drug interactions, adverse effects, and recommendations for monitoring in patients treated with cyclosporine. The use of cyclosporine in pregnancy and in the pediatric population is also addressed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据